Inhibikase Therapeutics, Inc.
3350 Riverwood Parkway, Suite 1900
Atlanta, GA 30339
November 12, 2020
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-3720
|Re:||Inhibikase Therapeutics, Inc.|
Registration Statement on Form S-1
SEC File No. 333-240036
Ladies and Gentlemen:
Reference is made to that certain letter, filed as correspondence via EDGAR on November 6, 2020, in which Inhibikase Therapeutics, Inc. (the “Company”) requested that the effective date of the Company’s Registration Statement on Form S-1 (File No. 333-240036) (the “Registration Statement”) be accelerated so that the Company’s Registration Statement would become effective on Tuesday, November 10, 2020, at 5:00 p.m. (Eastern Time), or as soon thereafter as practicable. The undersigned, on behalf of the Company, is no longer requesting that the Registration Statement become effective at this time and hereby formally withdraws such request.
|Inhibikase Therapeutics, Inc.|
|By:||/s/ Milton H. Werner, Ph.D.|
|Name: Milton H. Werner, Ph.D.|
|Title: President, Chief Executive Officer|
Cc: Merrill M. Kraines, Troutman Pepper Hamilton Sanders LLP